Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sarepta Therapeutics Inc.
DescriptionRNA-based influenza therapeutic based on phosphorodiamidate morpholino oligomer (PMO) technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase I
Standard IndicationInfluenza virus
Indication DetailsTreat influenza A (H1N1) virus infection; Treat influenza virus infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today